MedTrace Logo

Study of AzaSite Versus Vigamox in the Tears of Healthy Volunteers

NCT00575367 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2011-09-22

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the drug concentrations of AzaSite compared to Vigamox in tears of healthy volunteers

Conditions

Interventions

DRUG

AzaSite (azithromycin ophthalmic solution)

One drop ophthalmic solution at Visit 2

DRUG

Vigamox (moxifloxacin hydrochloride ophthalmic solution)

One drop ophthalmic solution at Visit 2

Sponsors & Collaborators

Principal Investigators

  • Reza Haque, MD · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2008-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00575367 on ClinicalTrials.gov